Magnesium Chloride Patents (Class 424/681)
-
Patent number: 7838532Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: GrantFiled: May 18, 2006Date of Patent: November 23, 2010Assignee: Mpex Pharmaceuticals, Inc.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
-
Publication number: 20100233295Abstract: This application relates to water-based personal moisturizers and lubricants that relive vaginal dryness. These compositions are non-spermicidal, sperm- and egg-friendly, and in various embodiments may mimic biological fluids, enhance sperm survival and motility, promote binding of sperm to eggs, and/or facilitate the process of fertilization. Related articles, systems, and methods of preparation and use of the compositions are also provided.Type: ApplicationFiled: February 28, 2007Publication date: September 16, 2010Inventors: Vibha Gupta, Vineet Gupta, Boris Nikolic
-
Publication number: 20100226867Abstract: The present invention provides a base composition that allows for the formulation of non-irritating cosmetic and/or dermatological compositions. The base composition includes one or more of electrolyte, buffer, mild preservative, lubricant, or any combinations thereof. It is preferred that one or more of the above components are eye-safe and/or eye-compatible. The present invention also provides photoprotective cosmetic and/or dermatological compositions that include the base composition and one or more sunscreen active components and are non-irritating to mammalian eyes.Type: ApplicationFiled: May 17, 2010Publication date: September 9, 2010Inventors: Olga V. Dueva-Koganov, James P. SaNogueira
-
Publication number: 20100183736Abstract: The present invention relates to a composition for the relief of hangover symptoms and methods of treating hangover symptoms.Type: ApplicationFiled: August 8, 2007Publication date: July 22, 2010Inventor: Evan Hays
-
Patent number: 7758900Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.Type: GrantFiled: February 23, 2007Date of Patent: July 20, 2010Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter C. Chang, Jean-Michel Lannoy
-
Publication number: 20100151054Abstract: An emulsion lotion composition including a) a partially hydrolyzed polyvinyl alcohol having a degree of saponification of 70 to 96 mol %, b) a carboxyvinyl polymer, c) an oil component at not greater than 40 mass % relative to the total compositional amount, at least 60 mass % of the contained oil component being a liquid oil, and d) an inorganic salt, the pH being 3.5 to 8.5, and the viscosity at 25° C. being 30 mPa·s to 310 mPa·s by oscillation viscometer, is an emulsion lotion composition that can be stored stably for a long period of time without adding a surfactant, has an excellent feeling when used, and can be prepared simply. This enables it to be used as an external preparation such as a pharmaceutical or a cosmetic.Type: ApplicationFiled: July 19, 2006Publication date: June 17, 2010Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Yoshinori Nishioku, Yasuyuki Suzuki, Aya Marumoto, Osamu Kondo
-
Publication number: 20100136141Abstract: A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material.Type: ApplicationFiled: July 13, 2009Publication date: June 3, 2010Inventors: Gary J. Pond, John Baeten
-
Patent number: 7713554Abstract: The subject invention provides a process and apparatus for making “enhanced water” that is uniquely suitable for improving circulation, hydration and insulin usage with diabetics. Thus, in a preferred embodiment, the invention provides methods for the treatment and/or prevention of diabetes as well as the prevention or delay in development of diabetes-related complications, conditions or diseases.Type: GrantFiled: March 1, 2005Date of Patent: May 11, 2010Assignee: Wellness Enterprises, LLCInventor: Harusuke Naito
-
Patent number: 7687078Abstract: Compositions for treating anal and vaginal inflammations while maintaining normal vaginal floral activity utilizing magnesium and alkali metal salts at an acidic pH.Type: GrantFiled: October 5, 2005Date of Patent: March 30, 2010Inventor: Scott Cordray
-
Patent number: 7678389Abstract: There is provided a method of treating irritations and inflammation of the eye or ear by the topical administration of an aqueous composition containing magnesium, potassium and sodium halides. The eye treating compositions have an osmolarity between 140 and 180 mOsm/l and are hypotonic.Type: GrantFiled: June 16, 2004Date of Patent: March 16, 2010Inventor: Scott Cordray
-
Patent number: 7658952Abstract: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.Type: GrantFiled: October 11, 2007Date of Patent: February 9, 2010Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Bruce L. Riser, Paul Zieske, Sujatha Karoor, Himanshu D. Patel
-
Publication number: 20100003314Abstract: The present invention relates to a method and composition for the treatment of skin conditions such as acne. Either natural or artificial sea water is enhanced by the addition of magnesium until it is at least about double the normal natural concentration of magnesium and then used as an application to the skin such as the face for treating acne and improving the appearance of the skin.Type: ApplicationFiled: July 2, 2008Publication date: January 7, 2010Inventor: Kenneth L. Willeford
-
Publication number: 20100003315Abstract: The present invention relates to artificial seawater and its use to treat a variety of skin conditions, when that sea water has more magnesium in it than in naturally occurring seawater. The treatment of acne would healing and the like can be improved with the product of the present invention and with treatments thereof.Type: ApplicationFiled: December 8, 2008Publication date: January 7, 2010Inventor: Kenneth L. Willeford
-
Publication number: 20090246254Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.Type: ApplicationFiled: April 3, 2009Publication date: October 1, 2009Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
-
Publication number: 20090221989Abstract: Disclosed is a system that prevents the development of infection and biofilm establishment in medical devices in general, and in particular Urinary Tract Infections (UTI), including Catheter-Associated Urinary Tract Infections (CAUTI). The system comprises of a medical device (such as a catheter) and an antimicrobial composition containing an antimicrobial compound. A medical device delivers the composition both to the inside and/or outside portions of the device, as well as to the inside of the bladder itself and to the urethra. Reduction or elimination of the infection may be accomplished by irrigating the medical device, bathing the bladder, or irrigating the bladder with the composition.Type: ApplicationFiled: September 21, 2006Publication date: September 3, 2009Inventors: Ramin Najafi, Mansour Bassiri, Lu Wang, Behzad Khosrovi
-
Patent number: 7560123Abstract: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in subjects undergoing physiologically stressful events, such as, for example and without limitation, pregnancy, lactation or any disease state.Type: GrantFiled: August 12, 2004Date of Patent: July 14, 2009Assignee: Everett Laboratories, Inc.Inventors: John A. Giordano, Charles J. Balzer
-
Publication number: 20090169648Abstract: The invention discloses compositions that effectively reduce and stabilize glucose levels in the blood of mammals, specifically in pre-diabetic patients and patients with type 2 diabetes mellitus (T2DM). Composition 1 (Comp1) reinforces efficacy of Mg salt to reduce glucose level by the combination of Mg salt with anti-inflammatory agents konjac-glucomannan (KGM), vitamin C and alpha-lipoic acid (?-LA). Composition 2 (Comp2) provides safety for chromium picolinate (CrPic) by the combination of CrPic with anti-inflammatory agents KGM, vitamin C and ?-LA that inhibits oxygen radicals. Compositions may optionally include cinnamon extract (CE) or another insulinogenic nutraceutical agent, American ginseng (AG), Uncaria tomentosa, Uncaria guianensis and Urtica dioica.Type: ApplicationFiled: March 3, 2009Publication date: July 2, 2009Applicant: Astrum Therapeutics Pty LtdInventors: Eric Hayes, Alexander Zolotoy
-
Patent number: 7544301Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.Type: GrantFiled: August 19, 2004Date of Patent: June 9, 2009Assignee: HHD LLCInventors: Dilip H. Shah, Todd Ing
-
Patent number: 7541052Abstract: The present invention provides hypertonic solutions for treating irritations and inflammations of the nasal passageways. The solutions contain magnesium salts and calcium salts.Type: GrantFiled: December 23, 2005Date of Patent: June 2, 2009Inventor: Scott Cordray
-
Publication number: 20090117205Abstract: The present invention relates to a pharmaceutical solution comprising the following components (A) and (B): (A) a compound represented by the following formula (1): or a salt thereof, or a hydrate thereof; and (B) a multivalent metal compound, wherein molar ratio of the component (B) to component (A) (the multivalent compound/component (B)) is 0.01 to 0.7. A pharmaceutical solution adapted for intravascular administration containing the quinolone compound at a therapeutically sufficient amount is provided, and this solution exhibits reduced toxicity even when the multivalent metal compound were incorporated at a reduced amount.Type: ApplicationFiled: July 1, 2005Publication date: May 7, 2009Applicant: Daiichi Pharmaceutical CO., LTDInventors: Emi Yano, Hideo Kobayashi, Hiroshi Kikuchi, Yuri Yamaguchi, Toshimasa Jindo, Norihiro Nishimoto
-
Patent number: 7476660Abstract: The present invention relates to a composition for organ preservation, comprising an inulin type fructan as an active ingredient. The composition for organ preservation can suppress the hypofunction of an organ and damage to a histological structure and can improve the state of preservation of the organ in the course of organ transplantation and the like.Type: GrantFiled: March 28, 2003Date of Patent: January 13, 2009Assignee: Meiji Seika Kaisha, Ltd.Inventors: Yoshihiko Masaki, Kazunari Yoshida, Tadao Endo, Hirofumi Nakamura, Yasuhito Tashiro
-
Patent number: 7432308Abstract: The equilibrium between G actin and F actin is shifted towards the F actin confirmation with compounds such as the ionic form of magnesium or potassium. The higher amount of F actin decreases the inhibition of nucleases such as DNAse I by monomeric G actin. The increased performance of the nuclease results in better treatment of patients suffering from cystic fibrosis or other diseases with viscous mucus.Type: GrantFiled: April 15, 2002Date of Patent: October 7, 2008Assignee: Universiteit GentInventors: Joseph Demeester, Stefaan De Smedt, Niek Sanders
-
Publication number: 20080241277Abstract: An herbal formulation including Symphytum Officinalis extract and Phytolacca Decandra extract may be combined to treat bone fractures and osseum defects. Specifically, the herbal formulation provides for the regeneration of osseum tissue for treating bone defects such as imperfect osteogenesis, pseudo-arthrosis infected or not, bone union delay of fractures, osteoporosis, osseum tumors, aneurismatic osseum cyst, and myeloma multiple.Type: ApplicationFiled: April 1, 2008Publication date: October 2, 2008Inventor: Alfredo Avila
-
Publication number: 20080213393Abstract: This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.Type: ApplicationFiled: March 13, 2008Publication date: September 4, 2008Applicant: Salix Pharmaceuticals, Inc.Inventors: Stephen Skiendzielewski, Martin Rose, Ngoc Do
-
Patent number: 7419680Abstract: Compositions useful in the prevention and treatment of osteoporosis and for bone and fracture repair. Slow-releasing calcium phosphate-based materials are disclosed, incorporating Mg, Zn, F and carbonate, which will promote bone formation and inhibit bone resorption and thus be agents for the cited uses.Type: GrantFiled: September 28, 2004Date of Patent: September 2, 2008Assignee: New York UniversityInventor: Racquel Z. LeGeros
-
Patent number: 7387799Abstract: The present invention relates to an anti-bacterial, anti-viral, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having catalytic function; (B) ionic compound, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.Type: GrantFiled: July 29, 2003Date of Patent: June 17, 2008Assignee: Well-Being Biochemical Corp.Inventors: Jih-Ru Hwu, Shwu-Chen Tsay
-
Patent number: 7345029Abstract: The present invention relates to a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. The avoidance of a glucose-like degradation as well as hydrolysis during sterilization and storage while maintaining a neutral mixture pH is achieved according to the invention by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further relates to a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.Type: GrantFiled: April 18, 2003Date of Patent: March 18, 2008Assignee: Fresenius Medical Care Deutschland GmbHInventor: Thomas Zimmeck
-
Patent number: 7335384Abstract: The present disclosure describes a novel composition for the treatment and/or prevention of neurogenic inflammation. Such composition is also useful in the treatment and/or prevention of disease states and conditions associated with neurogenic inflammation. Such disease states and conditions include, but are not limited to, migraine headache, arthritis and fibromyalgia. The composition comprises nutrient compounds in a novel combination and formulation to treat and/or prevent neurogenic inflammation and disease states and conditions associated therewith. By reducing neurogenic inflammation, the compositions of the present disclosure reduce the symptoms associated with neurogenic inflammation, such as pain and systemic inflammation in general.Type: GrantFiled: March 17, 2006Date of Patent: February 26, 2008Assignee: 4K Nutripharma InternationalInventor: F. Mahnaz Khaled
-
Publication number: 20080031904Abstract: The present invention relates to a combination useful in the fields of cosmetics, therapeutics and/or nutrition, for acting in particular against stress conditions, characterised in that it consists of (?) a sustained release preparation (I) comprising, in association with a physiologically acceptable excipient, a mixture of: (A) magnesium derived from a magnesium source consisting of MgO, MgCl2 and hydrates of the formula MgCl2·nH2O, where n is a whole or fractional number greater than 0 or equal to 6, (B) at least one substance selected from among (B1) a hydrophilic polymer, which is a cellulose derivative, and/or (B2) a hydrophobic substance belonging to the family of fatty acid esters and the mixtures thereof, and (C) an inert filler acting as diluent, in particular lactose; and (?) an active substance (Z), which is in particular selected from among plant extracts, yeast extracts, algae extracts, hormones, proteins, peptides, amino acids, unsaturated fatty acids and mixtures thereof.Type: ApplicationFiled: November 23, 2005Publication date: February 7, 2008Inventor: Fabienne Menvielle-Bourg-Joanny
-
Publication number: 20070281043Abstract: A microbicidal composition comprising relatively high levels of a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one; a metal nitrate; and water. The composition optionally contains magnesium chloride.Type: ApplicationFiled: May 29, 2007Publication date: December 6, 2007Inventors: Mary Jo Bergbauer, John Vincent Berrier, Richard Walter Nichols
-
Patent number: 7300649Abstract: Compositions, kits and methods are provided for restoring skin barrier function to skin exposed to environmental elements and/or in a pathological condition. In general, divalent cations such as calcium ions and/or magnesium ions are included in a physiologically acceptable medium. In some embodiments, divalent cations are balanced with monovalent cations such as sodium and potassium ions at appropriate ratios in order to maintain the homeostasis of skin barrier. The compositions, kits and methods can be used as cosmetics, cosmeceuticals or pharmaceuticals for improving skin condition, and preventing or treating dermatological diseases and skin disorders.Type: GrantFiled: February 8, 2006Date of Patent: November 27, 2007Assignee: GenePharm, Inc.Inventors: Hanafi Tanojo, Xinfan Huang
-
Patent number: 7300674Abstract: The present invention relates to a sterile calcium-free low bicarbonate dialysis concentrate composition for use in conjunction with regional citrate anti-coagulation in the context of either dialysis or hemofiltration. Methods of use of the sterile calcium free low bicarbonate dialysis concentrate compositions are also disclosed. The low bicarbonate concentrate takes into account the fact that citrate is hepatically metabolized into bicarbonate, thus minimizing metabolic complications.Type: GrantFiled: December 19, 2001Date of Patent: November 27, 2007Inventor: Sheldon Tobe
-
Patent number: 7279183Abstract: Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.Type: GrantFiled: December 24, 2003Date of Patent: October 9, 2007Assignee: Cedars-Sinai Medical CenterInventors: Sanjay Kaul, Prediman K. Shah
-
Patent number: 7255882Abstract: Benzodiazepine withdrawal induced anxiety is treated by administration of an enkephalinase inhibitor, and a gamma-aminobutyric acid (“GABA”) precursor, or an endorphin or enkephalin releaser. These components promote restoration of normal neurotransmitter function and are non-addictive. Use of the enkephalinase inhibitor D-phenylalanine, the GABA precursor glutamine, the serotonin precursor 5-HTP, glycine, and taurine, in combination with coenzymatic functionality of folic acid is preferred for activation of ligand-gated Cl? channel in the central nervous system. Food supplement embodiments provide the human body nutritional supplements to intake certain neurotransmitter precursor substrates, thereby enabling patients of all ages to self-regulate their ability to quell perturbations to equilibrium and simultaneously to adverse effects upon normal physiological and psychological functioning attributable to induced anxiety and panic associated with benzodiazepine withdrawal.Type: GrantFiled: October 29, 2004Date of Patent: August 14, 2007Inventors: Albert Howard Bieser, Terry Leo Neher
-
Patent number: 7186420Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.Type: GrantFiled: December 19, 2003Date of Patent: March 6, 2007Assignee: Edwards Lifesciences CorporationInventors: Peter C. Chang, Jean-Michel Lannoy
-
Patent number: 7097860Abstract: A method of reducing inflammation in a variety of disorders by using an intraperitoneal solution of magnesium. The solution can be used for treating inflammatory and inflammation-related disorders in animals and/or humans. Application of the solution reduces inflammation and thereby assists in the healing process. An alternative method involves the intraperitoneal administration of a solution containing magnesium salts. Another alternative method provides for treatment of inflammatory and inflammation-related disorders in animals by way of intraperitoneal administration of a solution containing magnesium salts, methenamine or its salts and dextrose. The method further provides the use of methenamine or its salts and/or dextrose in combination with magnesium.Type: GrantFiled: May 16, 2002Date of Patent: August 29, 2006Inventors: Aaron Moshenyat, Anna Moshenyat, Reuven Moshenyat, Yitzchak Moshenyat
-
Patent number: 7063865Abstract: A composition that will substantially reduce the deleterious effects of alcohol on the body and substantially reduce the side effects associated with hangovers (i.e. headaches, dizziness, nausea, dry mouth, etc) when taken as recommended. The composition includes an effective amount of (I)-glycine, (I)-glutathione, thiamine, magnesium, selenium, molybdenum. Other vitamins, mineral compounds, flavoring, coloring, and solubility agents may also be added.Type: GrantFiled: May 10, 2002Date of Patent: June 20, 2006Inventors: Jeremy Park Jones, Peter Kevin Dobler
-
Patent number: 6932966Abstract: A skin treatment mixture for treating pierced skin such as that resulting from a body piercing procedure includes sea salt, lysozyme and reconstituted ocean water. The reconstituted ocean water preferably is the product of reverse osmosis of water. The skin treatment mixture preferably additionally includes sodium benzoate to act as a preservative. A method of producing a skin treatment mixture includes the steps of providing a quantity of purified water; adding a quantity of sea salt to the quantity of purified water; boiling the purified water and sea salt; cooling the purified water and sea salt; adding a quantity of lysozyme to the purified water and sea salt; sterilizing the mixture and testing it for bacteria. A method of treating a pierced skin area includes the step of applying to the pierced area a reconstituted ocean water mixture of sea salt and lysozyme.Type: GrantFiled: June 20, 2003Date of Patent: August 23, 2005Inventor: Edward Kolos
-
Patent number: 6923987Abstract: A solid preparation for dialysis for preparing a double preparation type sodium bicarbonate solid preparation for dialysis in which there is no fear that a sugar component is decomposed or colored, and which can maintain stability and is also excellent in content homogeneity and a process for producing the same. The solid preparation for dialysis is a mixture of a first composition composed of core particles including sodium chloride and a coating layer containing one or more electrolytes, a second composition composed of core particles including a sugar that is covered with a coating layer comprising the same sugar or a different sugar, and an acid.Type: GrantFiled: September 27, 2001Date of Patent: August 2, 2005Assignee: Nipro CorporationInventors: Toshiya Kai, Kazuyuki Yamamoto, Kazutaka Fujiki, Makoto Sato
-
Patent number: 6908628Abstract: Wide spectrum disinfecting and antiseptic composition for use in the fields of human medicine, veterinary science and industry, characterized because it includes: Hydrogen peroxide, lactic acid and halogen salts (Br, I) and/or salts of heavy metals (for example, silver halides) with surfactant agents, either cationic, like chlorhexidine and/or quaternary ammonium salts, like didecyl-methyl-polyoxy-ethyl-ammonium propionate, chlorides of ammonium or compounds of ammonium propylamide or anionic, like lauryl sulphate, dodecyl sulphate or alkyl succinic salts, with suitable excipients, some of which may be ethyl or isopropyl alcohol, chlorhexidine, non-chlorinated quaternary ammonium salts, like didecyl-methyl-polyoxy-ethyl-ammonium propionate, combined or not with iodine, and/or its salts, together with excipients, some of which may be ethyl or isopropyl alcohol.Type: GrantFiled: June 10, 2002Date of Patent: June 21, 2005Assignee: OFTRAI, S.L.Inventor: Rafael Herruzo Cabrera
-
Patent number: 6884441Abstract: In contrast to the prior art, the essential components of dialyzing liquids are not provided as a dry concentrate or as a genuine solution at the place of dialysis, but as a suspension of undissolved or incompletely dissolved substances, preferably sodium chloride, optionally sodium acetate, in a solution of the remaining components. The suspension is prepared, stored, transported and used in a form designated as an acid cartridge or acetate cartridge, respectively. At the place of dialysis a liquid dialysis concentrate is prepared from the suspension by means of an apparatus, which is here suggested, and can be processed into dialyzing liquid with the existing dosing and safety systems of commercially available dialyzers. The prestage of a dialysis concentrate, which is described in this invention as a suspension, constitutes the supply form with the highest substance density for the components of acid and acetate-containing dialyzing liquids.Type: GrantFiled: August 30, 2002Date of Patent: April 26, 2005Assignee: Haas Medizintechnik GmbHInventors: Manfred Pippert, Uwe Hildmann, Hans-Gunther Eigendorf
-
Patent number: 6881424Abstract: A highly acidic metalated organic acid composition and its preparation. The acidic composition can be prepared by mixing a monovalent or polyvalent cation and an organic acid in the presence of a strong oxyacid, wherein the resultant acidic composition is less corrosive to a ferrous metal than a solution of a mineral acid having the same acidic pH value as that of the acidic composition, and where in the acid composition is more biocidal than a mixture of the organic acid and a metal salt of the organic acid which mixture has the same acid normality value as that of the acidic composition. The acidic composition can be prepared by mixing at least one regenerating acid, at least one metal base, and at least one organic acid, wherein the amount of the regenerating acid is in excess of the equivalent amount of the metal base.Type: GrantFiled: September 5, 2000Date of Patent: April 19, 2005Assignee: Mionix CorporationInventors: Maurice Clarence Kemp, Robert Blaine Lalum, David E. Lewis, Robert H. Carpenter
-
Patent number: 6867178Abstract: An enteral composition and method for providing nutrition to metabolically stressed patients. The enteral composition has an energy density of about 1.4 to 1.8 kcal/ml. The enteral composition includes a protein source providing 15% to 20% of the energy of the composition, a lipid source, and a carbohydrate source. The enteral composition has a ratio of non-protein calories per gram of nitrogen of at least about 90:1.Type: GrantFiled: December 30, 1998Date of Patent: March 15, 2005Assignee: Nestec S.A.Inventors: David A. Mark, Diana Twyman, Tom Michalski
-
Patent number: 6849595Abstract: The present invention provides an enteral composition and method for providing nutrition to metabolically stressed patients. Pursuant to the present invention, the enteral composition has an increased caloric density of approximately 1.4 to 1.8 kcal/mL. The enteral composition includes a peptide based protein source, a lipid source, and a carbohydrate source.Type: GrantFiled: January 10, 2001Date of Patent: February 1, 2005Assignee: Nestec S.A.Inventors: David A. Mark, Diana Twyman, Tom Michalski
-
Patent number: 6841551Abstract: A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.Type: GrantFiled: January 18, 2001Date of Patent: January 11, 2005Assignee: Hoffmann-La Roche Inc.Inventors: Alan John Nimmo, Robert Vink
-
Patent number: 6841172Abstract: The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is administered to a patient by transfer from dialysate. A complex selected according to the invention is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed into blood and the living body. Also provided are dialysate compositions including therein an iron complex selected according to the invention, and dialysate concentrates which may be diluted to yield an inventive dialysate composition.Type: GrantFiled: August 28, 1998Date of Patent: January 11, 2005Assignee: HemoCleanse, Inc.Inventor: Stephen R. Ash
-
Patent number: 6835398Abstract: A method of treating patients, particularly for pain and/or symptoms of erythromelalgia, and other neurovascular or neuropathic disorders, etc. involves administering high doses of magnesium. The magnesium is introduced through several daily administrations, totaling approximately 2-12 times the RDA for magnesium. These higher levels are achieved through increasing daily dosage amounts gradually in response to patient tolerance and until beneficial results are seen. Total magnesium intake is divided over several doses per day and taken with copious amounts of water.Type: GrantFiled: November 12, 2002Date of Patent: December 28, 2004Inventor: Jay S. Cohen
-
Publication number: 20040247642Abstract: Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.Type: ApplicationFiled: December 24, 2003Publication date: December 9, 2004Applicant: Cedars-Sinai Medical CenterInventors: Sanjay Kaul, Prediman K. Shah
-
Patent number: 6814984Abstract: The present invention is directed to frozen biocidal compositions. Specifically, the biocidal compositions comprise a frozen aqueous solution of a plurality of ions selected from the group consisting of halide and oxyhalide ions. The frozen biocidal compositions are useful in preserving or extending the shelf-life of perishable articles.Type: GrantFiled: February 8, 2002Date of Patent: November 9, 2004Assignee: Clean Water International LLCInventors: David C. Rose, Lawrence J. Ventura
-
Patent number: RE38604Abstract: Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized and cellular cofactor ratios are normalized in a manner which decreases toxicity over prior art solutions.Type: GrantFiled: February 1, 2002Date of Patent: September 28, 2004Assignee: BTG International LimitedInventor: Richard L. Veech